FDA Clearance Paves Way for Quantum BioPharma's Lucid-MS Phase 2 Trial in Multiple Sclerosis

Quantum BioPharma Ltd. (NASDAQ: QNTM) has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for Lucid-MS, enabling the company to proceed with a randomized, double-blind, placebo-controlled phase 2 trial in multiple sclerosis. The milestone positions Lucid-MS as a potential first-in-class therapy that takes a different approach from existing MS treatments by targeting the underlying demyelination process rather than suppressing the immune system.

Lucid-MS is a patented, non-covalent inhibitor of peptidyl arginine deiminase 2 (PAD2). In preclinical models, the compound has been shown to prevent and reverse myelin degradation, the mechanism that drives MS progression. By focusing on myelin repair, Quantum BioPharma aims to address a significant unmet need in MS care, where current therapies primarily modulate or suppress immune activity and often leave patients with progressive disability.

The FDA's acceptance of the IND application is a critical regulatory step. It allows Quantum to initiate human testing of Lucid-MS in a controlled trial design that can generate robust efficacy and safety data. A successful phase 2 outcome could attract partnership interest or accelerate the path to later-stage development, given the high burden of MS and the limited options for restoring damaged myelin.

In addition to the clinical advance, Quantum BioPharma is collaborating with Massachusetts General Hospital and Harvard Medical School on research involving the [¹⁸F]3F4AP PET imaging tracer. This tracer is being evaluated as a tool to visualize and measure demyelination, which could provide a biomarker for assessing treatment response and disease progression. If validated, such imaging could improve patient selection and monitoring in MS trials.

The broader context of the announcement includes other companies advancing therapies in areas of unmet need. Novartis AG (NYSE: NVS) recently received FDA approval for Pluvicto(R) in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer. Merck & Co. Inc. (NYSE: MRK) had its supplemental Biologics License Application for ENFLONSIA(TM) accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease. TG Therapeutics Inc. (NASDAQ: TGTX) initiated a phase 2 trial of BRIUMVI(R) in adults with treatment-resistant schizophrenia. Bristol-Myers Squibb Company (NYSE: BMY) reported positive phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma.

Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS. Quantum also invented UNBUZZD(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, and royalty rights. The company retains 100% of the rights to develop similar products for pharmaceutical and medical uses.

For investors, the FDA clearance represents a key de-risking event for Quantum's lead program. It demonstrates regulatory acceptance of the company's preclinical data and provides a clear pathway to human proof-of-concept. If Lucid-MS succeeds in phase 2, it could become a foundational therapy for MS, either as a standalone treatment or in combination with immunomodulators. The potential to reverse myelin damage, rather than just manage symptoms, could transform the treatment landscape for a disease that affects millions worldwide.

To view the full press release, visit https://ibn.fm/lCey9. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.